Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Manxiang Li (Xi'an, China), Dong Han, Yanting Zhu, Lu Liu, Yang Song, Manxiang Li. Activation of AMPK inhibits pulmonary arterial remodeling. Eur Respir J 2015; 46: Suppl. 59, 2443

Member's Comments

No comment yet.

Related content which might interest you: Inhibition of p38 MAPK improves heart function in experimental pressure-overload induced right ventricular hypertrophy and failure Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 ASK1 promotes maladaptive remodeling in a rodent model of pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Olfactory receptors in pulmonary arterial hypertension: A novel pathway of vascular remodeling? Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Inhibition of the miRNA familiy miR-130 restores the expression of CDKN1A (p21) and ameliorates hypoxia-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013 Inhaled INS1009 demonstrates localized pulmonary vasodilation activity Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 MIF/CD74 contributes to the endothelial pro-inflammatory phenotype in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Comparison of current therapies against endothelin-induced growth in pulmonary smooth arterial muscle cells (PASMCs) derived from patients with pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Increased Cyr61 in pulmonary arterial hypertension involving in proliferation of pulmonary arterial smooth muscle cells Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Modulation of symmetric dimethyarginine formation by apelin in human pulmonary endothelial cells Source: International Congress 2015 – Translational research in respiratory care: new findings Year: 2015 Intact serotonin signaling is not required for the development of severe angioproliferative pulmonary hypertension in rats Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 MicroRNA-155 controls pulmonary artery fibroblast cell signalling and proliferation in a knockout mouse model: A role in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Smad1 deficiency and female gender contribute to the development of pulmonary hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Acid sphingomyelinase, a novel pathway for pulmonary vasoconstriction. Activation by apoptotic T cell microparticles and Fas ligand Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Selective TSC1 deletion in smooth muscle activates mTOR signaling and induces pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015